Figari, C. A. S., Pizarro-Perea, M., Mallma, V., Valladares, G., Seminario, V., Ruiz, S. B., Chávez, L., Vera, M., Tornero, G. J., Menacho, E., Heredia-Vallejos, M., Calle, C., Castillo, C., Sánchez, J., Huamani, M. V. M., Rottier, C. A., Vargas, O., Untama, J. (2025). Dasatinib as 2nd line treatment is safe and effective in peruvian CML patients: A multicentric real-world study. Blood. https://doi.org/10.1182/blood-2025-7282